A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults
A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults
This will be an open-label, non-randomized, single oral dose study in healthy male subjects.
All subjects will receive a single oral dose of 10 mL of [14C]-RPC1063 Solution (0.1 mg/mL), containing NMT 1.3 MBq (37 μCi) 14C.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom, NG11 6JS
- Quotient Clinical
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is male
- Subject is 30 to 65 years of age
- Subject has a body weight of at least 50 kg; body mass index (BMI) of 18.0 to 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator
- Subject is willing and able to communicate and participate in the whole study
- Subject has regular bowel movements (average stool production ≥1 and ≤3 stools per day)
- Subject has suitable veins for multiple cannulation as assessed by the investigator at screening
- Subject is able to comprehend the informed consent form, provide written informed consent, and able to comply with requirements of the study.
- Subject agrees to use an adequate method of contraception
Exclusion Criteria:
- Subject has received any investigational medicinal product (IMP) in a clinical research study within the previous 3 months
- Subject is a study site employee or an immediate family member of a study site or sponsor employee
- Subject has a history of any drug or alcohol abuse in the past 2 years
- Subject has regular alcohol consumption of >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
- Subject is a current smoker or has smoked within the last 12 months; including cigarettes, e-cigarettes and nicotine replacement products. Positive cotinine test result at screening and admission
- Subject has radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
- Subjects has been enrolled in an absorption, distribution, metabolism and elimination (ADME) study in the last 12 months
- Subject has clinically significant abnormal biochemistry or haematology as judged by the investigator
- Subject has positive drugs of abuse test result
- Subject has positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
- Subject has evidence of renal impairment at screening and admission, as indicated by an estimated creatinine clearance (CLcr) of <90 mL/min using the Cockcroft-Gault equation
- Subject has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) concentration >1.25 × the ULN at screening
- Subject has history of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator
- Subject has had serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- Subject has presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
- Subject has donated or lost greater than 400 mL of blood within the previous 3 months
- Subject is taking, or has taken, any prescribed or over-the-counter drug (other than 2 g per 24 h paracetamol) dietary or herbal remedies within 14 days before IMP administration, or has taken St. John's wort within 28 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.
- Subject fails to satisfy the investigator of fitness to participate for any other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: [14C]-RPC1063 Solution (0.1 g/mL)
1 mg; 10 mL [14C]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of elimination of [14C]-RPC1063
Time Frame: Up to 4 weeks
|
Total recovery of radioactivity in urine and feces expressed as a percentage of total radioactive dose in each 24 h interval and cumulatively
|
Up to 4 weeks
|
|
Pharmacokinetic- amount of drug excreted
Time Frame: Up to 4 weeks
|
Cumulative amount of drug excreted unchanged in the drug in urine
|
Up to 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic- Cmax
Time Frame: Up to 8 days
|
Maximum observed concentration
|
Up to 8 days
|
|
Pharmacokinetic- Tmax
Time Frame: Up to 8 days
|
Time at maximum observed concentration
|
Up to 8 days
|
|
Pharmacokinetic- AUC0-last
Time Frame: Up to 8 days
|
Area under the curve from 0 time to last measurable concentration
|
Up to 8 days
|
|
Pharmacokinetic- AUC0-inf
Time Frame: Up to 8 days
|
Area under the curve from 0 time extrapolated to infinity
|
Up to 8 days
|
|
Pharmacokinetic- λz
Time Frame: Up to 8 days
|
Elimination rate constant
|
Up to 8 days
|
|
Pharmacokinetic- t1/2
Time Frame: Up to 8 days
|
Terminal elimination half-life
|
Up to 8 days
|
|
Pharmacokinetic- CL/F
Time Frame: Up to 8 days
|
Clearance, the apparent volume cleared of parent drug per unit time after extravascular administration
|
Up to 8 days
|
|
Pharmacokinetic- Vz/F
Time Frame: Up to 8 days
|
The apparent volume of distribution after extravascular administration
|
Up to 8 days
|
|
Pharmacokinetic- CLr
Time Frame: Up to 8 days
|
Renal clearance
|
Up to 8 days
|
|
Adverse Events (AEs)
Time Frame: Approximately 2 months
|
Number of participants with adverse events
|
Approximately 2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RPC01-1909
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.